Meeting
2017 ASCO Annual Meeting
Rhabdomyosarcoma (RMS) in adults: Histologic subtypes and overall survival with actinomycin-based chemotherapy vs doxorubicin-based chemotherapy.
Authors
Alia Vang
St. Olaf College, Northfield, MN
Alia Vang , Steven Ian Robinson , Scott H. Okuno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11073)
DOI
10.1200/JCO.2017.35.15_suppl.11073
Abstract #
11073
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy.
First Author: K. Harano
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2017 ASCO Annual Meeting
Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS).
First Author: Ewa Koscielniak
Poster
2016 ASCO Annual Meeting
Prognostic value of tumor response in pediatric and adult patients with Ewing sarcoma.
First Author: Melanie Ann Chihak